等待開盤 04-01 09:30:00 美东时间
+6.630
+6.90%
今日重点评级关注:HC Wainwright & Co.:维持Altimmune"买入"评级,目标价从12美元升至25美元;BTIG:维持Jade Biosciences"买入"评级,目标价从28美元升至39美元
03-17 11:45
U.S. RESEARCH ROUNDUP-Alnylam Pharmaceuticals, Cogent Biosciences, Summit Therapeutics March 16 (Reuters) - Wall Street securities analysts revised their ratings and price targets on several U.S.-listed companies including Alnylam Pharmaceuticals, Cogent Biosciences and Summit Therapeutics on Monday
03-16 18:00
Shares of semiconductor companies are trading lower amid overall market weaknes...
03-12 23:53
Biohaven shares rose in premarket trading after Xenon's Phase 3 epilepsy study showed strong seizure reduction results.
03-09 23:47
DAWN周涨一倍,获国际制药集团Servier溢价收购;Ziff Davis周涨56.3%,将其下属部门出售给埃森哲,获巴克莱上调其目标价;TNGX周涨52.1%,Q4亏损同比收窄超预期>>
03-07 10:50
Eli Lilly's lung cancer trial shows lower recurrence risk and strong survival benefit in early-stage patients.
02-17 19:42
As AI disruption hits several sectors, below is a list of small- and mid-cap semiconductor stocks that carry Strong Sell or Sell recommendations under the Quant Rating system and are ranked by their p...
02-14 04:21
Impinj meldet für das Gesamtjahr 2024 einen Nettoertrag von 40,84 Mio. USD, eine Veränderung um das 1,94-Fache Impinj Inc. hat die Finanzergebnisse für das Gesamtjahr (FY) zum 31. Dezember 2025 veröffentlicht. Der Umsatz belief sich auf 361,08 Mio. USD. Das Unternehmen erzielte einen Bruttogewinn vo
02-10 05:17
Impinj posts FY2025 net loss of USD 10.85 million, reversing from prior year's profit Impinj Inc. reported its full year (FY) 2025 financial results, posting revenue of USD 361.08 million. Gross profit for the period reached USD 189.68 million. Research and development expenses totaled USD 102.62 mi
02-10 05:17
今日重点评级关注:HC Wainwright & Co.:维持NovaBridge Biosciences"买入"评级,目标价从7美元升至9美元;Truist Securities:维持Reddit"买入"评级,目标价从270美元升至275美元
02-09 14:37